Why Participate in our trials?
Clinical trials study whether or not new medicines, devices, or diagnostic techniques work and are safe for use. Patients choose to participate in clinical trials for a variety of reasons such as a desire to contribute to the greater good through science or access to cutting edge treatments. By participating in clinical trials they are frequently seen by highly trained experts in their field. Compensation for time and effort is sometimes offered for trial participation.
Clinical trials are carefully planned and meticulously reviewed by groups of health specialists called Institutional Review Boards. Patients participate exclusively as volunteers for studies and enroll only after a detailed informed consent process. Patient volunteers have the right to drop out of a trial at any time.
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment period in Subjects with Moderate to Very Severe COPD
Purpose: To assess the effects of BGF MDI relative to GFF MDI and BFF MDI on the rate of moderate or Severe COPD exacerbations
Idiopathic Pulmonary Fibrosis
Bellerophon Pulse Technologies LLC-PULSE-PHPF-001
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (iNO) IN SUBJECTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS ON LONG TERM OXYGEN THERAPY
Purpose: To evaluate the efficacy of iNO as determined by change in 6MWD (6 minute walk distance) in subjects with pulmonary hypertension associated with pulmonary fibrosis (PH-PF) currently receiving treatment with LTOT.
Pearl Therapeutics PT001102
A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-Label Spiriva Respimat in Subjects With Persistent Asthma
Purpose: To asses the effect of 3 doses of GP MDI compared to Placebo MDI and Spiriva Respimat on Lung Function over 24 weeks in subjects with persistent asthma.
Interstitial Lung Disease
Boehringer Ingelheim- BI 1199.247
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Purpose: To investigate the efficacy and safety of 150 mg bid nintedanib over52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).
Scleroderma associated with Interstitial Lung Disease
A double blind, randomized, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD).
Purpose: To investigate the efficacy and safety of 150 mg bid nintedanib in
patients with Systemic Sclerosis associated Interstitial Lung Disease.
We are not currently enrolling for Bronchiectasis trials, but we are constantly reviewing new studies for future enrollment.
We are not currently enrolling for PE/DVT trials, but we are constantly reviewing new studies for future enrollment.
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)
Purpose:The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24 in subjects with PH associated with HFpEF.